$2.1M spinal muscular atrophy drug gains European approval

Alan Condon -   Print  |

The European Commission recently approved Zolgensma, Novartis' $2.1 million gene therapy drug for spinal muscular atrophy, for infants and children up to 46 pounds.

Zolgensma was developed by AveXis, a biotechnology company acquired by Novartis for $8.7 billion in 2018.

AveXis is negotiating with governments and reimbursement agencies to decide on terms of the "Day One" access program, which would provide rapid access in all countries in the European Union.

In May 2019, the FDA approved Zolgensma for infants under the age of 2, with the drug totalling $361 million in sales last year.

Zolgensma recently gained approval in Japan. Novartis expects decisions to be made by Swiss, Canadian and Australian authorities in late 2020 or early 2021.

More articles on biologics:
28.4M elective surgeries could be canceled in 2020 — orthopedic procedures hit hardest
Research finds lowest average cost of hip, knee replacements at 3 New York City hospitals
Texas orthopedic group snares 2 paycheck protection program loans

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers